Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Atomoxetine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel carbonyl reductase mutant enables high-purity chiral intermediate synthesis with reduced solvent waste and cost for pharmaceutical supply chains.
Patent CN1950326A details a high-yield optical resolution and recycling process for atomoxetine intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN104805142A enables high-purity Tomoxetine via enzyme catalysis. Reduces cost and improves supply chain reliability for pharmaceutical intermediates manufacturing.